Used in the treatment of type 2 diabetes, (R)-L888607 acts as a potent and selective agonist for the GPR119 receptor. Activation of GPR119 enhances glucose-dependent insulin secretion and promotes the release of incretin hormones such as GLP-1 and GIP. This dual action helps regulate blood sugar levels with a reduced risk of hypoglycemia. Due to its mechanism, it is investigated for improving glycemic control and supporting weight management in diabetic patients. Its receptor selectivity may also contribute to a favorable safety profile, making it a candidate for once-daily oral therapy in metabolic disorders.